GRFS - Grifols, S.A.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.12
-0.03 (-0.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close22.15
Open22.15
Bid20.27 x 3200
Ask22.12 x 900
Day's Range21.97 - 22.24
52 Week Range17.42 - 22.50
Volume703,683
Avg. Volume1,389,054
Market Cap19.58B
Beta (3Y Monthly)1.13
PE Ratio (TTM)36.90
EPS (TTM)0.60
Earnings DateN/A
Forward Dividend & Yield0.35 (1.59%)
Ex-Dividend Date2019-06-07
1y Target Est21.67
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    Grifols presents additional encouraging Alzheimer's trial results at AAIC

    BARCELONA, Spain, July 16, 2019 /PRNewswire/ -- The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's at the Alzheimer's Association International Conference (AAIC) 2019 in Los Angeles (USA).

  • Company News for Jul 8, 2019
    Zacks12 days ago

    Company News for Jul 8, 2019

    Companies In The News Are: OASM,GOL,GRFS,DELL

  • How Much Are Grifols, S.A. (BME:GRF) Insiders Spending On Buying Shares?
    Simply Wall St.12 days ago

    How Much Are Grifols, S.A. (BME:GRF) Insiders Spending On Buying Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...

  • This Pharma Stock Dodged A Broad Slide For Drugmakers — Here's Why
    Investor's Business Daily15 days ago

    This Pharma Stock Dodged A Broad Slide For Drugmakers — Here's Why

    Shares of Grifols popped in massive volume Friday after the Spain-based pharmaceutical company gained Food and Drug Administration approval for an immunodeficiency treatment.

  • Benzinga15 days ago

    The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight

    The following is a roundup of the top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs July 3.) • Abbott Laboratories (NYSE: ABT ) • Apellis ...

  • PR Newswire16 days ago

    Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

    BARCELONA, Spain, July 4, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S. Food and Drug Administration (FDA).  Xembify® is used to treat primary immunodeficiencies.

  • PR Newswire17 days ago

    Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa

    BARCELONA, Spain, July 3, 2019 /PRNewswire/ -- Grifols (GRF.MC) (GRF.P.MC) (GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb, a provider of hemodialysis solutions headquartered in Morocco, as the main supplier for a new manufacturing plant in northern Africa. Grifols will develop, build and automate the main process equipment for the IV solutions line.  Grifols Engineering, which provides technology and consultancy services to the pharmaceutical and biotech sectors, will design a state-of-the-art manufacturing line that will produce intravenous solutions bags. This is the first industrial project for Grifols on the African continent.

  • Is Grifols SA (GRFS) A Good Stock To Buy ?
    Insider Monkey20 days ago

    Is Grifols SA (GRFS) A Good Stock To Buy ?

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • PR Newswirelast month

    Grifols to launch plasma-protein-based bleeding-control solutions

    BARCELONA, Spain, June 19, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that the VISTASEAL™ fibrin sealant will be the first product it will introduce with Ethicon Inc. as part of a broad global relationship to provide plasma-protein-based solutions to manage surgical bleeding. Grifols developed VISTASEAL™, which combines two plasma proteins, fibrinogen and thrombin, and is administered with Ethicon's airless spray device technology.

  • Is Rigel Pharmaceuticals a Buy?
    Motley Foollast month

    Is Rigel Pharmaceuticals a Buy?

    The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?

  • Do Institutions Own Grifols, S.A. (BME:GRF) Shares?
    Simply Wall St.last month

    Do Institutions Own Grifols, S.A. (BME:GRF) Shares?

    Every investor in Grifols, S.A. (BME:GRF) should be aware of the most powerful shareholder groups. Insiders often own...

  • George Soros' Top 6 New Buys of the 1st Quarter
    GuruFocus.com2 months ago

    George Soros' Top 6 New Buys of the 1st Quarter

    Top buys include entertainment company Comcast and homebuilder D.R. Horton

  • GRFS or ORINY: Which Is the Better Value Stock Right Now?
    Zacks2 months ago

    GRFS or ORINY: Which Is the Better Value Stock Right Now?

    GRFS vs. ORINY: Which Stock Is the Better Value Option?

  • Rigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Rigel Pharmaceuticals Inc (RIGL) Q1 2019 Earnings Call Transcript

    RIGL earnings call for the period ending March 31, 2019.

  • PR Newswire3 months ago

    Grifols Announces PharmacyKeeper Bidirectional Integration with Epic

    BARCELONA, Spain, April 30, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, announced today that its PharmacyKeeper Verification IV Workflow Management system now supports bidirectional integration with Epic.

  • PR Newswire3 months ago

    Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia

    Investing $1.6 million into local community; set to employ over 40 people from the local area HINESVILLE, Ga. , April 29, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...

  • What Does Grifols, S.A.'s (BME:GRF) P/E Ratio Tell You?
    Simply Wall St.3 months ago

    What Does Grifols, S.A.'s (BME:GRF) P/E Ratio Tell You?

    This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how Grifols, S.A.'s (BME:GRF) P/E ratio could help you assess the value on offer...

  • PR Newswire3 months ago

    Grifols US donor centers exceed 250,000 pounds of food collected

    - About 20% of children in the U.S. are frequently hungry while nearly 50 million Americans do not get enough to eat. RALEIGH, N.C., April 18, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its U.S. network of over 220 donor centers collaborated with local food banks and pantries to collect more than 250,000 pounds of groceries to help address food insecurity in local communities. According to Feeding America, a leading national hunger non-profit, the 253,000 pounds of food collected translates into 211,000i meals to help support the over 50,000 familiesii that cannot put sufficient food on the table.

  • Grifols donations of blood clotting factor helping people with hemophilia globally
    PR Newswire3 months ago

    Grifols donations of blood clotting factor helping people with hemophilia globally

    - The company has donated more than 100 million international units (IUs) of blood clotting factor medicines globally during multi-year commitment to the WFH in developing regions. - Grifols creates Grifols Humanitarian Awards in Hemophilia to strengthen the global fight against the disease. BARCELONA, Spain, April 15, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with hemophilia in developing regions has surpassed 100 million international units (IUs) in donated blood clotting factor, a protein in blood that controls bleeding.

  • PR Newswire3 months ago

    Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019

    BARCELONA, Spain , April 5, 2019 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United ...

  • Grifols, S.A. (BME:GRF): What We Can Expect From This Growth Stock
    Simply Wall St.4 months ago

    Grifols, S.A. (BME:GRF): What We Can Expect From This Growth Stock

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Looking at Grifols, S.A.'s (BME:GRF) earnings update in December 2018, the cons...

  • Should You Buy Grifols SA (GRFS)?
    Insider Monkey4 months ago

    Should You Buy Grifols SA (GRFS)?

    "October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • PR Newswire4 months ago

    Grifols Announces the Opening of its new Plasma Donor Center in Russellville, AR

    Investing $1.8 million into local community; set to employ over 40 people from the local area RUSSELLVILLE, Ark. , March 23, 2019 /PRNewswire/ -- Grifols is pleased to announce the opening of a new Biotest ...

  • Reuters4 months ago

    Spain's Grifols, China's Shanghai RAAS form strategic alliance

    Spanish blood products company Grifols said on Thursday it has signed a strategic alliance with Shanghai RAAS as it looks to increase its sales of plasma-derived products in China. Under the agreement, the Catalan company will take a 26.2 percent stake in Shanghai RAAS in exchange for a stake of 45 percent (with 40 percent voting rights) in its U.S. division Grifols Diagnostic Solutions (GDS). Grifols said that no external financing was required to fund the transaction which is expected to close in the second half of 2019 pending regulatory approval.